Physician profile
Sayed M Aamir
NPI 1083745863
$8,639.22
in general payments reported to CMS, 2019-2025
52 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,787 · 2020: $452 · 2021: $885 · 2022: $1,338 · 2023: $1,455 · 2024: $1,424 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,110 · Education: $68.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,109.66 |
| Education | $68.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,648.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $876.89 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Vivus LLC | $446.07 | 2019-2025 | Qsymia |
| Amgen INC. | $391.02 | 2019-2025 | Tepezza, Evenity, Prolia |
| Mannkind Corporation | $376.63 | 2019-2025 | Afrezza |
| Abbott Laboratories | $324.14 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $288.13 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $280.77 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Ibsa Pharma INC. | $252.82 | 2019-2024 | Tirosint, Licart, Tirosint |
| Astrazeneca Pharmaceuticals LP | $239.89 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $219.88 | 2022-2025 | |
| Insulet Corporation | $219.36 | 2019-2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.90 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.66 | 2019-2023 | Cycloset |
| Abbvie INC. | $194.65 | 2019-2025 | Synthroid |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $174.89 | 2022-2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $137.58 | 2019-2023 | Steglatro |
| Beta Bionics, INC. | $129.78 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $122.61 | 2022-2025 | Korlym |
| Tandem Diabetes Care, INC. | $121.99 | 2019-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $120.72 | 2019-2021 | |
| Dexcom, INC. | $112.41 | 2019-2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $110.91 | 2019-2023 | Contrave, Nexletol, Nexlizet |
| Esperion Therapeutics, INC. | $110.81 | 2021-2024 | Nexletol |
| Amneal Pharmaceuticals LLC | $110.24 | 2019-2024 | Unithroid |
| Medtronic Minimed, INC. | $82.47 | 2019-2020 | |
| Shire North American Group INC | $80.15 | 2019 | |
| Radius Health, INC. | $77.02 | 2024-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $72.97 | 2019-2021 | |
| Antares Pharma, INC. | $66.98 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $63.25 | 2019 | |
| Senseonics, Incorporated | $62.00 | 2019-2020 | |
| Becton, Dickinson and Company | $61.80 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $61.40 | 2020-2022 | |
| Madrigal Pharmaceuticals | $57.10 | 2025 | Rezdiffra |
| Topcon Healthcare Solutions, INC. | $53.26 | 2020 | |
| Horizon Therapeutics Plc | $48.26 | 2022 | |
| Sequel Med Tech, LLC | $47.02 | 2025 | Twiist |
| Medtronic, INC. | $43.14 | 2021-2023 | Minimed 780g |
| Amphastar Pharmaceuticals, INC. | $40.26 | 2024-2025 | |
| Valeritas, INC. | $38.72 | 2019 | |
| Alfasigma USA, INC. | $32.34 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $28.94 | 2019-2021 | |
| Ascendis Pharma Endocrinology INC | $28.64 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $28.27 | 2025 | |
| Verity Pharmaceuticals INC. | $24.71 | 2025 | Trelstar |
| Embecta Corp. | $23.60 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ascensia Diabetes Care US INC. | $20.18 | 2024 | |
| Endo Pharmaceuticals INC. | $19.50 | 2019 | |
| Aegerion Pharmaceuticals, INC. | $18.72 | 2019 | |
| Globus Medical, INC. | $18.00 | 2025 | Senza |
| Assertio Therapeutics, INC. | $17.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Aamir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.